Porous Silk Membrane Bioreactor for Platelet Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing platelets are inefficient, resulting in high costs and waste due to short shelf life, limited availability, and risks associated with disease transmission and acute reactions, with existing technologies unable to produce sufficient quantities or maintain platelet functionality effectively.
Innovation Solution
A bioreactor system using a porous silk membrane with stromal derived factor-1α and a three-dimensional silk matrix is developed to stimulate megakaryocytes to produce differentiated and functional platelets, achieving higher yields and improved functionality compared to previous methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If platelet concentrates are collected from volunteer donors using current methods, then platelets are obtained for transfusion, but the production cost is high, shelf life is short (5 days), and 20-40% are discarded
Solution Approach 1:
The patent replaces mechanical collection methods (apheresis machines, manual processing) with a biologically-driven system where megakaryocytes automatically produce platelets in response to SDF-1α gradients and shear stress, eliminating the need for complex mechanical separation equipment and reducing operational complexity
Solution Approach 2:
The invention changes the production parameters by controlling shear stress (0.5-5 dyn/cm²), SDF-1α concentration (10-100 ng/mL), and oxygen tension (5-21%) to optimize platelet yield and quality, transforming the production process from a passive collection system to an actively controlled biological manufacturing system
2Duration of action of stationary object
If platelets are stored with current methods, then they are available for transfusion, but shelf life is limited to 5 days and cannot be easily shipped from surplus to scarcity areas
Solution Approach 1:
The system performs preliminary platelet production by differentiating megakaryocytes into platelets before transfusion, creating a stable, long-lived product that can be stored and transported without the urgency and limitations of current same-day-use platelet concentrates
Solution Approach 2:
The invention uses a disposable, biodegradable hydrogel microbead system that eliminates the need for expensive, complex storage infrastructure, allowing platelets to be produced, stored, and shipped in simple, low-cost containers that maintain platelet viability without specialized equipment
3Reliability
If platelet transfusions are administered to patients, then platelet deficiency is treated, but patients are exposed to risks of disease transmission, acute reactions, and alloimmunization
Solution Approach 1:
The system creates an idealized, controlled copy of the bone marrow microenvironment using hydrogel beads with specific mechanical properties (elastic modulus 0.1-10 kPa) and biochemical cues (SDF-1α, extracellular matrix proteins), producing platelets in a sterile, pathogen-free setting that eliminates disease transmission risks while maintaining physiological functionality
Solution Approach 2:
The hydrogel microbead system creates an inert, controlled environment that protects megakaryocytes from contamination and adverse reactions, isolating the production process from external pathogens and immune system interference to ensure safe, reactive-free platelet generation
4Quantity of substance
If existing bioreactor systems are used to produce platelets, then some platelet production is achieved, but the yield is insufficient and platelet functionality is not maintained effectively
Solution Approach 1:
The system applies local quality control by creating distinct microenvironments on the hydrogel bead surfaces with specific extracellular matrix proteins (fibronectin, collagen, laminin) and growth factor concentrations, allowing megakaryocytes to receive localized signals that optimize both platelet production quantity and functional quality in different spatial zones
Solution Approach 2:
The invention uses composite hydrogel materials combining natural polymers (alginate, collagen, fibrin) with synthetic components and embedded bioactive molecules, creating a multifunctional scaffold that simultaneously supports cell adhesion, provides mechanical cues, delivers growth factors, and maintains platelet functionality throughout the production process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system produces significantly more platelets (0.8×10^6 to 2.0×10^6) in 6 hours, with 70% expressing CD61 and maintaining functionality, including binding to PAC-1 after stimulation, addressing the inefficiencies and risks of current methods.
Implementation Method 1
a porous silk membrane between about 2-100 μm thick, inclusive, comprising at least one silk wall defining a lumen
Implementation Method 2
associating the porous silk membrane with stromal derived factor-1α
Implementation Method 3
stimulating the plurality of megakaryocytes to produce platelets
Data Source
AI summary
The present invention provides, among other things, methods for producing platelets including the steps of providing a silk membrane about 2 μm and 100 μm thick, inclusive, contacting the silk membrane with a porogen to form a porous silk membrane comprising at least one silk wall defining a lumen, associating the porous silk membrane with stromal derived factor-1? and at least one functionalizing agent, forming a three dimensional silk matrix comprising interconnected pores wherein the pores have a diameter of between about 5 and 500 μm, inclusive, wherein the silk matrix is formed around at least a portion of the porous silk membrane, introducing a plurality of megakaryocytes to the silk matrix such that the megakaryocytes are located at least partially within the porous silk matrix, and stimulating the plurality of megakaryocytes to produce platelets. Also provided are various new compositions and methods of making those compositions.